Continuing Pharmacy Education / CE Master List / IIMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

IIMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Describe at least one important change (or proposed change) in childhood and adult vaccination recommendations put forth by the CDC and/or ACIP
  • Given a patient who inquires about receiving respiratory virus or bacteria vaccinations (e.g., Influenza, COVID-19, Respiratory Syncytial Virus (RSV), Pneumococcal), outline important differences between multiple products when they exist
  • Identify evidence-based pharmacotherapeutic treatments for common vaccine-preventable illnesses

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-069-H06-P

Session Code

25RW69-MGF85

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-069-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeffery Aeschlimann, PharmD
Associate Clinical Professor-Infectious Disease Specialty
University of Connecticut School of Pharmacy
Storrs, CT  

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Aeschlimann consults with F2G, Inc. but there is no crossover in the topics, so all issues have been mitigated.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

  1. Which of the following recommendations did ACIP approve in 2025?
    1. All adults receive single dose thimerosal-free seasonal influenza vaccine formulations free
    2. State and local jurisdictions should require a prescription for the administration of a COVID-19 vaccination
    3. COVID-19 vaccination should be administered to all adults 55 and older
  2. Baby Boy Blue develops measles today; the rash is widespread on his body and he cries incessantly. He has three unvaccinated siblings. His mom asks what the contagious period is and how contagious the infection is. What is the CORRECT answer?
    1. Measles are contagious for roughly five days after the rash’s appearance, and they are not terribly contagious.
    2. Measles are contagious for plus or minus five days of the rash’s appearance, and they are highly contagious.
    3. Measles are contagious only in the week before the rash’s appearance, and they are highly contagious.
  3. Mom is surprised and braces herself for all of her children to contract measles; she heard that taking an antiviral will help. She asks if there is a pill that will help. What do you say?
    1. The FDA has not approved any antiviral therapies to treat measles.
    2. The most appropriate antiviral is daily vitamin A for at least 14 days.
    3. She should ask her pediatrician for a prescription for acyclovir.
  4. Mom is very concerned. She asks if there is anything she can do to protect her other children. Is there?
    1. No, she needs to ride out the storm and rethink her stance on vaccinations.
    2. Yes, she should ask a family member to host her children until Baby Boy Blue is better.
    3. Yes, her children can get post-exposure prophylaxis with MMR vaccine within 72 hours
  5. The ACIP panel voted to remove the option to use the MMRV vaccine in children younger than 47 months old. Why?
    1. ACIP cited slightly higher risks of tonic-clonic seizures for MMRV vs. separately administered doses of MMR & VARIVAX
    2. ACIP cited slightly higher risks of petit mal seizures for MMRV vs. separately administered doses of MMR & VARIVAX
    3. ACIP cited a slightly higher risks of fevers/febrile seizures for MMRV vs. separately administered doses of MMR & VARIVAX
  6. Two children of 2700 in a premarketing study experienced seizures after receiving the MMRV vaccine. What other characteristic did they share?
    1. They appeared to have a concurrent viral illness during vaccination.
    2. They appeared to have a vitamin A deficit of longstanding duration.
    3. They appeared to have contracted a cold shortly after vaccination.
  7. How many doses of hepatitis B vaccine are necessary to achieve protection at the 95% level?
    1. One
    2. Two
    3. Three
  8. A 70-year-old male comes to the consultation window of your pharmacy. He would like to receive a vaccination for the flu. His only chronic health issues are hypertension and hypercholesterolemia (both effectively managed). You have three vaccines in stock. Which of the following products would be PREFERRED to administer to this patient?
    1. Inactivated influenza vaccine (IIV3, Afluria)
    2. High-dose inactivated influenza vaccine (HD-IIV3, Fluzone High-Dose)
    3. Adjuvanted inactivated influenza vaccine (aIIV3, Fluad)

VIDEO